Stephen Shore, MD
Hematology & Oncology · Broomall, PANPI 1336235183
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 286 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 9.2% — the pattern of someone who eats at a lot of different presentations.
Across 286 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$581
- Shield Therapeutics Inc$565
- AstraZeneca$463
- Novartis$348
- Bristol Myers Squibb$285
- Pharmacyclics LLC, An Abbvie Company$272
- plus $4K from 51 others
Across 13 payments — averaging $1533.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$16K
- Incyte Corporation$3K
- AstraZeneca$234
What the payments were for
- Food & beverage$6,06696%
- Education$2684%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALIYA SYSTEM$134
- Enhertu$115
- Abraxane$110
- OPDIVO$107
How this compares
$6,334 in reported general payments places this provider in the 70th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 13 | $212,700 |
| RevlimidLenalidomide | 16 | $208,807 |
| IbrancePalbociclib | 15 | $181,560 |
| TecentriqAtezolizumab | 15 | $156,488 |
| TavalisseFostamatinib Disodium | 11 | $142,229 |
| PromactaEltrombopag Olamine | 11 | $140,025 |
| EliquisApixaban | 74 | $78,989 |
| XareltoRivaroxaban | 22 | $28,434 |
| AranespDarbepoetin Alfa In Polysorbat | 12 | $21,863 |
| Imatinib Mesylate | 16 | $3,404 |
| Hydroxyurea | 52 | $984 |
| Warfarin Sodium | 41 | $875 |
| Anastrozole | 19 | $583 |
| Famotidine | 72 | $512 |
| Prednisone | 100 | $401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $180 | $260,54989 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $272 | $212,70013 claims |
| Bristol Myers SquibbRevlimid | $285 | $208,80716 claims |
| NovartisPromacta | $348 | $140,02511 claims |
| Johnson & JohnsonXarelto | $186 | $28,43422 claims |
| AmgenAranesp | $109 | $21,86312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Broomall
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.